Merz + Articles

Combination treatment with memantine and ChEI suggests a comprehensive effect on patients with Alzheimer’s

13 September 2011

Neurobiological Tech gets $2M Merz milestone

10 November 2008

Neurobiological gets $1.4M royalty for memantine

6 February 2006

Forest's Namenda becomes first FDA-approved therapy for advanced AD

27 October 2003

Merz Pharma-US president Conrad becomes CEO of Merz Inc

11 August 2003

Tokyo pharma stocks - week to March 25

1 April 2002

Celexa driving earnings at Forest

19 July 2001

Cipramil sales driving Lundbeck growth

16 May 2001

Neurobio Tech gets memantine milestone from Merz

3 May 2001

Lundbeck profits soar 54% in 2000 as citalopram sales boom

7 March 2001

Merz' memantine of benefit in Alzheimer's

18 July 2000

Stock Commentary New York

13 July 2000

Merz + Co and Forest link up for memantine

6 July 2000

Merz & Co's memantine in vascular dementia

12 April 2000

Merz signs cooperation deal with Grunenthal

9 February 2000

Merz completes memantine studies in Alzheimer's

4 November 1999

Further evidence for memantine efficacy in dementia

5 March 1999

Merz Signs Memantine Deal

23 April 1998

Allergan Gains Memantine License From Merz & Co

19 May 1997

Prospects For Glutamate Antagonists In Stroke

18 September 1995

ELDERLY HEALTH CARE: JAPAN'S SITUATION

3 February 1992

ALZHEIMER'S DISEASE: A GROWING BURDEN

20 January 1992

Showing 1-22 of 22 articles

Go to beginningPrevious
  • 1
NextGo to end